13.02 USD
-0.22 (-1.66%)
13.02 USD
0 (0%)
IART gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of IART while its profitability can be described as average. IART is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IART was profitable.
IART had a positive operating cash flow in the past year.
IART had positive earnings in 4 of the past 5 years.
IART had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
IART's Return On Assets of -13.58% is in line compared to the rest of the industry. IART outperforms 58.82% of its industry peers.
IART's Return On Equity of -47.74% is in line compared to the rest of the industry. IART outperforms 52.94% of its industry peers.
IART has a better Return On Invested Capital (4.27%) than 74.33% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IART is below the industry average of 8.81%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROIC | 4.27% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
IART has a Operating Margin of 10.22%. This is in the better half of the industry: IART outperforms 78.61% of its industry peers.
IART's Operating Margin has declined in the last couple of years.
IART has a Gross Margin (57.21%) which is comparable to the rest of the industry.
IART's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IART is creating some value.
Compared to 1 year ago, IART has less shares outstanding
The number of shares outstanding for IART has been reduced compared to 5 years ago.
The debt/assets ratio for IART is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.26, we must say that IART is in the distress zone and has some risk of bankruptcy.
IART's Altman-Z score of 1.26 is in line compared to the rest of the industry. IART outperforms 54.55% of its industry peers.
A Debt/Equity ratio of 1.73 is on the high side and indicates that IART has dependencies on debt financing.
The Debt to Equity ratio of IART (1.73) is worse than 79.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.26 |
ROIC/WACC0.76
WACC5.65%
2.3 Liquidity
IART has a Current Ratio of 3.14. This indicates that IART is financially healthy and has no problem in meeting its short term obligations.
IART has a Current ratio of 3.14. This is comparable to the rest of the industry: IART outperforms 58.29% of its industry peers.
A Quick Ratio of 1.80 indicates that IART should not have too much problems paying its short term obligations.
The Quick ratio of IART (1.80) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
IART shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.44%.
IART shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.35% yearly.
IART shows a small growth in Revenue. In the last year, the Revenue has grown by 4.99%.
The Revenue has been growing slightly by 1.20% on average over the past years.
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
3.2 Future
Based on estimates for the next years, IART will show a small growth in Earnings Per Share. The EPS will grow by 2.68% on average per year.
IART is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.39% yearly.
EPS Next Y-12.33%
EPS Next 2Y-3.14%
EPS Next 3Y1.48%
EPS Next 5Y2.68%
Revenue Next Year1.09%
Revenue Next 2Y1.9%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 5.49, the valuation of IART can be described as very cheap.
Based on the Price/Earnings ratio, IART is valued cheaply inside the industry as 97.86% of the companies are valued more expensively.
IART's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.34.
IART is valuated cheaply with a Price/Forward Earnings ratio of 5.42.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IART indicates a rather cheap valuation: IART is cheaper than 98.93% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.56, IART is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.49 | ||
| Fwd PE | 5.42 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IART is valued cheaply inside the industry as 94.12% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.97 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.14%
EPS Next 3Y1.48%
5. Dividend
5.1 Amount
IART does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
13.02
-0.22 (-1.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.55%
Inst Owner Change0%
Ins Owners3.07%
Ins Owner Change0.07%
Market Cap1.01B
Revenue(TTM)1.64B
Net Income(TTM)-495.33M
Analysts54.12
Price Target15.81 (21.43%)
Short Float %9.76%
Short Ratio6.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.96%
Min EPS beat(2)2.22%
Max EPS beat(2)21.7%
EPS beat(4)3
Avg EPS beat(4)7.07%
Min EPS beat(4)-6.76%
Max EPS beat(4)21.7%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)3.64%
EPS beat(16)8
Avg EPS beat(16)4.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.86%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-4.85%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-1.23%
Revenue beat(12)2
Avg Revenue beat(12)-1.2%
Revenue beat(16)3
Avg Revenue beat(16)-0.96%
PT rev (1m)-8.82%
PT rev (3m)-5.65%
EPS NQ rev (1m)-1.23%
EPS NQ rev (3m)-12.58%
EPS NY rev (1m)0.04%
EPS NY rev (3m)-0.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.75%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)-2.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.49 | ||
| Fwd PE | 5.42 | ||
| P/S | 0.62 | ||
| P/FCF | N/A | ||
| P/OCF | 11.36 | ||
| P/B | 0.98 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.97 |
EPS(TTM)2.37
EY18.2%
EPS(NY)2.4
Fwd EY18.45%
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)1.15
OCFY8.81%
SpS21.09
BVpS13.32
TBVpS-9.47
PEG (NY)N/A
PEG (5Y)N/A
Graham Number26.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROCE | 5.11% | ||
| ROIC | 4.27% | ||
| ROICexc | 4.65% | ||
| ROICexgc | 11.32% | ||
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexgc growth 3Y-1.99%
ROICexgc growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.62 | ||
| Cap/Depr | 68.73% | ||
| Cap/Sales | 6.32% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 28.01% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 1.26 |
F-Score5
WACC5.65%
ROIC/WACC0.76
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
EPS Next Y-12.33%
EPS Next 2Y-3.14%
EPS Next 3Y1.48%
EPS Next 5Y2.68%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
Revenue Next Year1.09%
Revenue Next 2Y1.9%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
EBIT growth 1Y-9.4%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.44%
EBIT Next 3Y9.51%
EBIT Next 5Y8.11%
FCF growth 1Y-113.18%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-46.39%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%
INTEGRA LIFESCIENCES HOLDING / IART FAQ
Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a fundamental rating of 4 / 10 to IART.
Can you provide the valuation status for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a valuation rating of 6 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Fairly Valued.
How profitable is INTEGRA LIFESCIENCES HOLDING (IART) stock?
INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 4 / 10.
What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?
The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 3 / 10.